GALECTIN THERAPEUTICS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GALECTIN THERAPEUTICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($30.84M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($47.05M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($41.07M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($38.78M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($30.53M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($23.47M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($13.29M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($13.90M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($16.24M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($21.44M) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.09M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($42.43M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($38.07M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($38.35M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($30.18M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($23.44M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($13.44M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($13.60M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($16.25M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($21.48M) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.29M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $36.57M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $32.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $31.74M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $23.82M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $17.98M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $7.47M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.47M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $11.72M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $15.33M | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.88M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($41.77M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($32.97M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($31.06M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($24.31M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($20.60M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($10.85M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($10.18M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($15.89M) | Mar 6, 2019 |
| FY2013 | Dec 31, 2013 | ($7.48M) | Mar 21, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $0 | Mar 15, 2016 |
| FY2015 | Dec 31, 2014 | $0 | Mar 15, 2016 |
| FY2015 | Dec 31, 2013 | $0 | Mar 15, 2016 |
| FY2014 | Dec 31, 2012 | $5.0K | Mar 18, 2015 |
| FY2012 | Dec 31, 2011 | $5.0K | Mar 29, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.53M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $17.50M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $28.20M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $21.29M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $41.83M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $29.60M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $48.47M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $9.01M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $4.16M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $15.80M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.73M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $120.57M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $88.44M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $53.48M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $39.21M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.41M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.87M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.11M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $2.97M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $3.78M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($127.92M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($104.79M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($61.96M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($33.92M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $893.0K | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $22.47M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $43.87M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $5.18M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | ($530.0K) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $10.29M | Mar 6, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($432.55M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($401.57M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($354.37M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($309.57M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($270.69M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($240.00M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($216.39M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($196.22M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($181.17M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($163.70M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.72M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $15.12M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $25.66M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.59M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $39.65M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $27.14M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $47.48M | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | $8.25M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $3.05M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $15.36M | Mar 6, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 65.20M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 63.16M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 61.85M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 59.43M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 59.34M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 57.08M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 56.89M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 41.19M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 35.79M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 32.91M | Mar 29, 2018 |